News Updates in Prostate Cancer 

Newsletters from Dr. Charles K. Metzger, MD, MBA

Each newsletter includes links to detailed articles

This is the nail in the coffin for the mri vs ultrasound debate. Not only will it get the process back into the urologist office, away from the radiologist there will be less reluctance to do guided biopsies.

May14_edited.png

May 14, 2022

Here is a current update from Johns Hopkins to their 2011 original article regarding active surveillance for prostate cancer. 

ActiveSurveillance_edited.png

May 7, 2022

The FDA officially approved these agents which will be discussed in our next talk, on Thursday, April 24, 2022 at 7 pm. Please attend and find out how all this fits together.

Stethescope_edited.png

April 22, 2022

An extensive review of the literature about pre treatment of advanced disease with different therapies (neoadjuvant) prior to surgery or radiation

StackOfBooks_edited.png

April 9, 2022

Exciting Announcements

Here are two exciting new developments for the prostate cancer world. The first is treatment for men with metastatic prostate cancer that is hormone sensitive. Really impressive results. The second is the use of LU PSMA for treatment of end stage disease and its approval for use by the FDA in castrate resistant prostate cancer.

MedicalScience.jpg

March 26, 2022

Informational Video Update on IsoPSA Test

This very informative video presentation by Dr. Eric A. Klein, MD is another example of progress in the decision about how to use PSA and who needs more testing.

https://www.urologytimes.com/view/dr-eric-klein-on-the-impressive-performance-of-isopsa-in-recent-study

Presentation_edited.jpg

March 13, 2022

Prostate-Specific Antigen–Based Screening Ushers in an Era of Change

This is a very interesting review of the history of PSA.  Lots of twists and turns in its life as a screening tool.  Using it wisely is really the key to its existence.

PSA_edited.png

March 5, 2022

Although controversial, the trend is to treat the main tumor even if there is oligometastasis (less than five sites).

Scanning_edited.jpg

February 26, 2022

This is the near future of prostate imaging.

Ultrasound_edited.png

January 29, 2022

German hospitals are offering a 3-4 day inpatient treatment called Lutetium 177. 

Pill_edited.jpg

January 10, 2022

The FDA has approved piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer- it is finally official.

AwarenessRibbon.png

January 4, 2022

The Exablate system, which uses high intensity ultrasound to control locally-confined prostate cancer,  is very precise for the treatment of focal prostate cancer.

AwarenessRibbon.png

November 13, 2021

This is another step forward in the theranostics arena.

Theranostics_edited.png

November 13, 2021

This is a succinct look at the field of immunotherapy as it relates to prostate cancer. It’s a great overview of current and future treatment options.

AwarenessRibbon.png

November 1, 2021

This article answers a question at the advance meeting of the value of pre op multi parametric MRI (this was pre PSMA work) in determining if surgery is the way to go. 

AwarenessRibbon.png

October 11, 2021

The PSMA-PET imaging agents Piflufolastat F 18 and Gallium 68 PSMA-11 are approved by the FDA for managing patients with prostate cancer

AwarenessRibbon.png

September 26, 2021

This very long article really is the answer to where MRI fits into the diagnostic scheme of elevated PSA.

MRI-Targeted_edited_edited.png

September 11, 2021

It was just a matter of time before another promising agent was added to the PSMA.

AwarenessRibbon.png

Sept 3, 2021

The following articles help put to rest the value of MRI fused biopsy and compares it to the regular ultrasound guided biopsy

AwarenessRibbon.png

July 31, 2021

These articles show the amazing advances in the treatment of advanced prostate cancer.

AwarenessRibbon.png

July 17, 2021

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.

Meeting_edited_edited.png

April 27, 2021

ORGOVYX, the drug that will eventually replace Lupron or Zoladex for the treatment of advanced prostate cancer, is now readily available. This is the only androgen deprivation therapy (ADT) medicine that is not given in the form of an injection.

PillBottle_edited_edited.png

April 10, 2021

The use of MRI guided transurethral approach to just treat a solitary lesion is now gaining traction as a way to do a more directed minimally invasive treatment.

FocalTherapy_edited.jpg

April 3, 2021

A really good review of the use of active surveillance in all age groups. Emphasis on clinical guidelines and non-medical factors, like Vitamin D, low-dose statin, and frequent biomarkers for disease status.

ActiveSurveillance.jpg

March 18, 2021

Scientists are making great strides when it comes to the gene editing technique known as CRISPR. Scientists are confident that the treatment and prevention of prostate cancer using CRISPR technique holds tremendous potential.

DNA_edited.png

March11, 2021

Scientists are making great strides when it comes to the gene editing technique known as CRISPR. Scientists are confident that the treatment and prevention of prostate cancer using CRISPR technique holds tremendous potential.

JointApproach.jpg

February 25, 2021

The incidence of prostate cancers that have spread to the bone at diagnosis has increased since the PSA test was taken off the guidelines of the U.S. Preventative Services Task Force (USPSTF). Some modification of this recommendation needs to be considered on a case-by-case basis.

PSAscreenings_edited.png

February 25, 2021

A shorter course of stereotatic body radiotherapy (SBRT) has been shown to be effective in high-risk prostate cancer. The toxicity has been favorable and the cost is competitive.

SBRT_edited_edited.png

February 16, 2021